These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32772054)

  • 21. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
    Ahmadi J; Jahromi MS; Ehsaei Z
    Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Faster, better, stronger: towards new antidepressant therapeutic strategies.
    O'Leary OF; Dinan TG; Cryan JF
    Eur J Pharmacol; 2015 Apr; 753():32-50. PubMed ID: 25092200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
    Smith KL; Cunningham JI; Eyerman DJ; Dean RL; Deaver DR; Sanchez C
    Neuropharmacology; 2019 Mar; 146():316-326. PubMed ID: 30448421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the genetic aspects of resistance to antidepressants treatment.
    Alqahtani AM; Kumarappan C; Kumar V; Srinivasan R; Krishnaraju V
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7784-7795. PubMed ID: 32744705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidepressant-like effects of buprenorphine in rats are strain dependent.
    Browne CA; van Nest DS; Lucki I
    Behav Brain Res; 2015 Feb; 278():385-92. PubMed ID: 25453747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.
    Lauterbach EC
    Psychopharmacol Bull; 2016 Aug; 46(2):53-58. PubMed ID: 27738380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
    Williams NR; Heifets BD; Blasey C; Sudheimer K; Pannu J; Pankow H; Hawkins J; Birnbaum J; Lyons DM; Rodriguez CI; Schatzberg AF
    Am J Psychiatry; 2018 Dec; 175(12):1205-1215. PubMed ID: 30153752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioidergic Agents as Antidepressants: Rationale and Promise.
    Saxena PP; Bodkin JA
    CNS Drugs; 2019 Jan; 33(1):9-16. PubMed ID: 30430396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant augmentation: good news, limitations, and stumbling blocks.
    Kocsis JH
    J Clin Psychiatry; 2015 Apr; 76(4):e526-7. PubMed ID: 25919849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
    Dunlop BW; LoParo D; Kinkead B; Mletzko-Crowe T; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
    Am J Psychiatry; 2019 Apr; 176(4):275-286. PubMed ID: 30764648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.
    de Sousa RT; Zanetti MV; Brunoni AR; Machado-Vieira R
    Curr Neuropharmacol; 2015; 13(5):616-35. PubMed ID: 26467411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Keeping up with the clinical advances: depression.
    Ragguett RM; Tamura JK; McIntyre RS
    CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
    Robinson SA; Erickson RL; Browne CA; Lucki I
    Behav Brain Res; 2017 Feb; 319():96-103. PubMed ID: 27818236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.